Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations
| العنوان: | Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations |
|---|---|
| المؤلفون: | Sabino De Placido, Paolo Solidoro, Giulia Bianchi, F. Testore, Lucia Del Mastro, Marina Cazzaniga, Daniele Generali |
| المساهمون: | Del Mastro, Lucia, Cazzaniga, Marina, Solidoro, Paolo, Generali, Daniele, Bianchi, Giulia, Testore, Franco, De Placido, Sabino, Del Mastro, L, Cazzaniga, M, Solidoro, P, Generali, D, Bianchi, G, Testore, F, De Placido, S |
| المصدر: | Future Oncology. 11:2251-2254 |
| بيانات النشر: | Future Medicine Ltd, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Receptor, ErbB-2, multidisciplinary follow-up, adverse event, Pharmacology, Neuroendocrine tumors, chemistry.chemical_compound, ErbB-2, Exemestane, Receptors, Antineoplastic Combined Chemotherapy Protocols, adverse events, breast cancer, compliance, dosing, everolimus, management, toxicity, Breast Neoplasms, Disease Management, Everolimus, Female, Humans, Medication Adherence, Neoplasm Staging, Receptors, Estrogen, Receptors, Progesterone, Progesterone, General Medicine, Breast Neoplasm, Receptor, Human, medicine.drug, medicine.medical_specialty, medicine.drug_class, Breast cancer, Internal medicine, medicine, Adverse effect, Antineoplastic Combined Chemotherapy Protocol, Aromatase inhibitor, business.industry, everolimu, Cancer, medicine.disease, Estrogen, adverse events, breast cancer, compliance, dosing, everolimus, management, multidisciplinary follow-up, toxicity, Clinical trial, chemistry, MED/06 - ONCOLOGIA MEDICA, business |
| الوصف: | Everolimus – an inhibitor of the mTOR pathway – has an established role in the treatment of advanced renal cell cancer (RCC), neuroendocrine tumors of pancreatic origin (pNET) and renal angiomyolipoma and tuberous sclerosis complex (TSC) [1]. Moreover, everolimus, combined with the aromatase inhibitor exemestane, has been approved for the treatment of postmenopausal patients with advanced breast cancer positive for the hormone receptors (HR + ) and negative for the HER2 - recurring or progressing after treatment with nonsteroidal aromatase inhibitors [2]. Everolimus is administered orally, at a dose of 10 mg/day continuously. At this dosage, no evidence of cumulative toxicity has been reported in clinical trials over a period of 20–52 weeks [2]. The optimal use of everolimus in breast cancer relies upon adequate management, in order to maximize treatment exposure and, therefore, optimize the clinical outcomes. However, since everolimus has only recently entered the breast cancer arena, physicians may be unfamiliar with its adverse event profile and their management. Given the low threshold for change in therapy in the breast cancer setting – which can be likely attributed to the availability of multiple treatment options – we believe that information on the correct management of everolimus-based treatment in breast cancer patients is important to improve outcomes. This editorial discusses some open issues related to the clinical management of breast cancer patients receiving everolimus. Management of adverse events Adverse events associated with everolimus might differ from those that oncologists endorsed to the breast cancer treatment are more familiar with. We comment on the management of some adverse events characteristic of everolimus therapy, namely stomatitis and noninfectious pneumonitis. Other specific considerations on the man agement of specific everolimus-associated “The multidisciplinary management of each single breast cancer case, based on the involvement of several medical specialists dedicated to cancer treatment ... may further improve patient’s compliance to the administered treatment and, therefore, the management of everolimus-based therapy in clinical practice.” |
| تدمد: | 1744-8301 1479-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9603c7215760bda613b37042f2f34dcTest https://doi.org/10.2217/fon.15.134Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....a9603c7215760bda613b37042f2f34dc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448301 14796694 |
|---|